Nayan Ashok Gujarathi

Nayan Ashok Gujarathi

Auto-generated profile, based on publicly available information

Nayan Ashok Gujarathi

Shri Vile Parle Kelavani Mandal’s Institute of Pharmacy, Dhule 424001, Maharashtra, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TPTulshidas S. Patil*
Tulshidas S. Patil*
NGNayan A. Gujarathi
Nayan A. Gujarathi
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
HPHemal E. Pachpande
Hemal E. Pachpande
CSCharu Sharma
Charu Sharma
YGYogeeta Agrawal Goyal
Yogeeta Agrawal Goyal
Psoriasis is linked with unusual differentiation and hyperproliferation of epidermal keratinocytes that significantly impair the quality of life (QoL) of patients. The present treatment options only provide symptomatic relief and are surrounded by various adverse effects. Recently, nanostructured lipid carriers (NLCs) have emerged as next-generation nanocarriers with better physicochemical characteristics. The current manuscript provides background information on psoriasis, its pathophysiology, existing treatment options, and its limitations. It highlights the advantages, rationale, and mechanism of the permeation of NLCs for the treatment of psoriasis. It further gives a detailed account of various NLC nanoformulations for the treatment of psoriasis. In addition, tabular information is provided on the most relevant patents on NLCs for treating psoriasis. Lastly, light is shed on regulatory considerations related to NLC-like nanoformulations. In the treatment of psoriasis, NLCs display a sustained release drug profile, an ability to incorporate both hydrophobic and hydrophilic drugs, an enhancement in skin hydration, penetrability, retention, and bioavailability of the drug, along with reduced staining potential as compared to conventional ointments, and decreased side effects of drug molecules. This affirms the bright future of NLC nanoformulations in the treatment of psoriasis. However, academic industry collaboration and more sound regulatory controls are required to commercialize the NLC nanoformulations for psoriasis treatment.

8 July 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KPKiran Dayaram Patil
Kiran Dayaram Patil
NGNayan Gujarathi
Nayan Gujarathi
CSCharu Sharma
Charu Sharma
Shreesh  OjhaShreesh Ojha
Shreesh Ojha
SGSameer Goyal
Sameer Goyal
YGYogeeta Agrawal Goyal
Yogeeta Agrawal Goyal
Apixaban, an anticoagulant, is limited in its efficacy due to poor solubility, low bioavailability, and extensive metabolism. This study investigates the application of nanostructured lipid carriers (NLCs) to enhance the bioavailability of Apixaban. NLCs were prepared using the high-pressure homogenization method. The influence of independent variables, viz., the amount of Tween 80, HPH pressure, and the number of HPH cycles, were studied using a 23 factorial design. The average particle size, PDI, zeta potential, and entrapment efficiency of the optimized NLCs were found to be 232 ± 23 nm, with 0.514 ± 0.13 PDI and zeta potential of about −21.9 ± 2.1 mV, respectively. Additionally, concerning the thermal and crystallographic properties of the drug, the NLCs showed drug entrapment without altering its potency. The in-vitro drug release studies revealed an immediate release pattern, followed by sustained release for up to 48 h. In-vivo pharmacokinetic experiments demonstrated that Apixaban-loaded NLCs exhibited higher values of t1/2 (27.76 ± 1.18 h), AUC0–∞ (19,568.7 ± 1067.6 ng·h/mL), and Cmax (585.3 ± 87.6 ng/mL) compared to free drugs, indicating improved bioavailability. Moreover, a decrease in the elimination rate constant (Kel) reflected the sustained effect of Apixaban with NLCs. NLCs offer improved oral absorption rates and enhanced therapeutic impact compared to free drugs, potentially reducing dose frequency and improving patient outcomes.

20 June 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TKTanaya D. Khairnar
Tanaya D. Khairnar
GCGaurav S. Chavan
Gaurav S. Chavan
MSMeenaz M. Sayyed
Meenaz M. Sayyed
NGNayan A. Gujarathi
Nayan A. Gujarathi
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
TPTulshidas S. Patil*
Tulshidas S. Patil*


10 July 2018 in Asian Journal of Pharmaceutical Research and Development
Verified
Journal Article
Open access
PDF file
JMJyotsna T Mahajan
Jyotsna T Mahajan
NGNayan Gujarathi
Nayan Gujarathi
AJAnil Jadhav
Anil Jadhav
VPVasim Pathan
Vasim Pathan
LBLakshmikant Borse
Lakshmikant Borse
The present investigation deals with the formulation, optimization and evaluation of liquid crystalline cream of Tolnaftate. Brij-78 used as a surfactant, Cetostearyl alcohol was used as a co-surfactant and Silicon oil as a oil phase. Liquid crystalline cream system, has a potential for efficient delivery of Tolnaftate (1%), as topical dermal drug delivery system. The liquid crystalline system enhance the diffusion of water insoluble drug Tolnaftate through the skin for effective result. Liquid crystals (LC) are substances that flow like liquids but maintain some of the ordered structure characteristics of crystalline solids. Based on the ways that LCs are generated, they can be classified into two types 1) Thermotropic LCS and 2) Lyotropic LCs. Incorporation of the drug in liquid crystal increased its antimycotic activity against different antifungal microorganisms. Used surfactant enhance the penetration of drug and also improve the solubility of drug. The objective of this study was to increase the diffusion coefficient of drug through the formulation, and also to improve the availability of drug at the site of action. The prepared liquid crystalline cream exhibited the expected, viscosity, drug content, pH, spreadability, in vitro drug release and in vitro antimycotic inhibitory activity. Liquid crystalline cream for tolnaftate was found to be stable cream. It was found to have better in vitrorelease profile characteristics, and in vitro antimycotic activity, it can be concluded that the formulation F5 has better potential of antimicrobial activity and to enhance the diffusion of drug through the cream.

14 June 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NGNayan A. Gujarathi
Nayan A. Gujarathi
RGRushikesh Girase
Rushikesh Girase
ASAmey Sukhia
Amey Sukhia
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
TPTulshidas S. Patil*
Tulshidas S. Patil*
SKSri Sai Nikitha Kota
Sri Sai Nikitha Kota